Drug Trial Radar · NCT07787325
Real-World Evaluation of Recombinant Human Prourokinase for Acute Ischemic Stroke Within 4.5 Hours
Last checked: Nov 20, 2026Latest source record: Aug 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
3,000
Planned (sponsor's estimate)
Start
Sep 11, 2026
Primary completion
Aug 31, 2029
Study completion Aug 31, 2029
Sponsor
- Lead sponsor
- The First Affiliated Hospital of Anhui Medical UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Aug 26, 2026
Design
- Study type
- Observational
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Acute ischemic stroke is a major cause of disability and death. Intravenous thrombolytic therapy is an important treatment option when given within the appropriate time window. Recombinant human prourokinase (rhPro-UK) is a thrombolytic medication approved for the treatment of acute ischemic stroke within 4.5 hours after symptom onset in China. This prospective, multicenter cohort registry study aims to evaluate the effectiveness and safety of intravenous rhPro-UK in patients with acute ischemic stroke treated within 4.5 hours of symptom onset. Approximately 3,000 patients from multiple centers will be enrolled and followed for 90 days. Clinical outcomes, bleeding events, adverse events, and functional recovery will be collected and analyzed to provide further evidence on the use of rhPro-UK in routine clinical practice.
Conditions
- Acute Ischemic Stroke
Interventions
Recombinant Human ProurokinaseDrug
Intravenous administration of recombinant human prourokinase for acute ischemic stroke within 4.5 hours of symptom onset. The total dose is 35 mg, consisting of a 15 mg intravenous bolus followed by 20 mg continuous infusion over 30 minutes.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Excellent Functional Outcome at 90 DaysTime frame: 90 days (±7 days) after treatment
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The First Affiliated Hospital of Anhui Medical University
Hefei, Anhui, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.